Scientists recommend wider use of clot-busting stroke drug

09/25/2008 | Wall Street Journal, The

A stroke drug from Genentech called tissue plasminogen activator, marketed as Activase in the U.S., can be administered 4 1/2 hours after the onset of stroke symptoms -- past the three-hour limit recommended by the FDA -- a study concluded. Researchers found that 52% of patients who received TPA more than three hours after suffering a stroke survived with little impairment based on the Rankin scale while the rate for those who got placebo was 45%. The study was conducted in Europe by Boehringer Ingelheim, Genentech's business partner.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA